Blog
RSS FeedPosted by Michael Wonder on 10 Jun 2024
SMC - June 2024 decisions
10 June 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 08 Jun 2024
Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria
29 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Jun 2024
New cancer drug funding to be announced this year, Christopher Luxon
4 June 2024 - Prime Minister Christopher Luxon says the government is aiming to make an announcement on funding cancer ...
Posted by Michael Wonder on 05 Jun 2024
Blood cancer doctors urge Government: don’t break drug promise to our patients
6 June 2024 - More pressure has come on the Government over PHARMAC funding as an alliance of haematologists and ...
Posted by Michael Wonder on 05 Jun 2024
Ivosidenib in combination with azacitidine for the first-line treatment of patients with IDH1 R132 mutation positive acute myeloid leukaemia (final guidance)
5 June 2024 - NICE has published final evidence-based guidance on the use of ivosidenib with azacitidine in the NHS ...
Posted by Michael Wonder on 05 Jun 2024
Nivolumab for the adjuvant treatment of patients 12 years and older with completely resected melanoma at high risk of recurrence
5 June 2024 - NICE is unable to make a recommendation on the use of nivolumab (Opdivo) for the adjuvant treatment ...
Posted by Michael Wonder on 04 Jun 2024
Mounjaro is second obesity drug to be approved for use in England
4 June 2024 - Those with BMI of at least 35 kg.m2 and a co-morbidity can now be prescribed tirzepatide and ...
Posted by Michael Wonder on 03 Jun 2024
New pharmacy agreement delivers cheaper medicines
3 June 2024 - The Albanese Government and the Pharmacy Guild of Australia have signed the eighth Community Pharmacy Agreement ...
Posted by Michael Wonder on 01 Jun 2024
New analysis examines role of conditional approvals on access to promising oncology therapies
31 May 2024 - Health Canada’s Notice of Compliance with conditions (NOC/c) policy has been effective in providing people in Canada ...
Posted by Michael Wonder on 01 Jun 2024
New Zealand Pharmaceutical Schedule - 1 June 2024
1 June 2024 - The June 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 May 2024
Schedule of Pharmaceutical Benefits - 1 June 2024
1 June 2024 - The June 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 May 2024
Improving our assessments of drugs with companion diagnostic tests
30 May 2024 - As part of our ongoing initiative to improve and modernise our reimbursement review program, Canada’s Drug Agency ...
Posted by Michael Wonder on 30 May 2024
Budget 2024 health: no funding for promised cancer drugs disappoints breast cancer patient - extension to screening welcomed
30 May 2024 - A cancer patient is disappointed with a lack of funding for new medicines in Budget 2024, ...
Posted by Michael Wonder on 29 May 2024
Zanubrutinib in combination with obinutuzumab for the treatment of patients with relapsed or refractory B-cell follicular lymphoma after two or more treatments
28 May 2024 - NICE is unable to make a recommendation on the use of zanubrutinib (Brukinsa) in combination with obinutuzumab ...
Posted by Michael Wonder on 29 May 2024
Dabrafenib mesylate in combination with trametinib dimethyl sulphoxide for the treatment of children and adolescents with BRAF V600E mutation positive glioma
29 May 2024 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Finlee) in combination with ...